Lancet

• Latest
• Best
• Search…

• Lancet · Feb 2020

  Editorial

  Looking beyond Brexit.

  no abstract available

  keep going… or not…

• Lancet · Feb 2020

  Editorial

  Safeguarding the health and livelihoods of migrants.

  no abstract available

  keep reading… or not…

• Lancet · Feb 2020

  What next for the coronavirus response?

  no abstract available

  read on… mark as read…

• Lancet · Feb 2020

  Decisions to be made on US gun violence research funds.

  no abstract available

  read on… or not…

• Lancet · Feb 2020

  Randomized Controlled Trial Multicenter Study

  Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.

  Dual neutralisation of interleukin 17A (IL17A) and interleukin 17F (IL17F) is a potential novel therapeutic approach in psoriatic arthritis. We assessed bimekizumab, a monoclonal antibody that selectively neutralises IL17A and IL17F, in patients with active psoriatic arthritis. ⋯ UCB Pharma.

  read more… or not…